The chemopreventive agent development research program in the Division of Cancer Prevention of the US National Cancer Institute: An overview

European Journal of Cancer

Volumn 41, Issue 13, 2005, Pages 1889-1910

  Crowell, James A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer prevention; Carcinogenesis; Chemoprevention; Drug development

Indexed keywords

3 INDOLEMETHANOL; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ANTINEOPLASTIC AGENT; CELECOXIB; CURCUMIN; CYCLOOXYGENASE 2 INHIBITOR; DAIDZEIN; DEGUELIN; DIETHYLSTILBESTROL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCOSAHEXAENOIC ACID; EFLORNITHINE; GENISTEIN; GLYCITEIN; IBUPROFEN; ICOSAPENTAENOIC ACID; INDOMETACIN; ISOFLAVONE DERIVATIVE; LICOFELONE; LYCOPENE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIROXICAM; POLYPHENOL DERIVATIVE; RESVERATROL; SR 13668; SULINDAC; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BLADDER CANCER; BREAST CANCER; CANCER; CANCER CENTER; CANCER PREVENTION; CANCER RESEARCH; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENTIATION; DRUG SCREENING; ENDOMETRIUM CANCER; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERTENSION; KIDNEY DISEASE; LUNG NON SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN CANCER; SYNTHESIS;

EID: 27644481208     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.04.016     Document Type: Article

References (239)

1. Sporn MB. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 1976, 36(7 PT 2), 2699-2702.
2. Wattenberg LW. Chemoprevention of cancer. Cancer Res 1985, 45(1), 1-8.
3. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer, report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998, 90(18), 1371-1388.
4. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000, 342(26), 1946-1952.
5. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003, 349(3), 215-224.
6. Vogel VG. Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts. Clin Cancer Res 2001, 7(12 Suppl.), 4413s-4418s., discussion 4411s-4412s.
7. Klein EA, Thompson IM, Lippman SM, et al. SELECT, the selenium and vitamin E cancer prevention trial. Urol Oncol 2003, 21(1), 59-65.
8. Reddy BS, Nayini J, Tokumo K, et al. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res 1990, 50(9), 2562-2568.
9. Jacoby RF, Seibert K, Cole CE, et al. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the Min mouse model of adenomatous polyposis. Cancer Res 2000, 60(18), 5040-5044.
10. Reddy BS, Hirose Y, Lubet R, et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 2000, 60(2), 293-297.
11. Grubbs CJ, Lubet RA, Koki AT, et al. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 2000, 60(20), 5599-5602.
12. Fischer SM, Lo HH, Gordon GB, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog 1999, 25(4), 231-240.
13. Solomon SD, McMurray JV, Pfeffer MA, et al. Cardiovascular risk associated with celebrex in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352(11), 1080-1091.
14. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005, 352(11), 1092-1102.
15. Zhu J, Song X, Lin HP, et al. Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. J Natl Cancer Inst 2002, 94(23), 1745-1757.
16. Shureiqi I, Lippman SM. Lipoxygenase modulation to reverse carcinogenesis. Cancer Res 2001, 61(17), 6307-6312.
17. Charlier C, Michaux C. Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. Eur J Med Chem 2003, 38(7-8), 645-659.
18. Shureiqi I, Chen D, Lee JJ, et al. 15-LOX-1, a novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells. J Natl Cancer Inst 2000, 92(14), 1136-1142.
19. Rose DP, Connolly JM. Omega-3 fatty acids as cancer chemopreventive agents. Pharmacol Ther 1999, 83(3), 217-244.
20. Chiang N, Bermudez EA, Ridker PM, et al. Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc Natl Acad Sci USA 2004, 101(42), 15178-15183.
21. Rigas B, Kashfi K. Nitric-oxide-donating NSAIDs as agents for cancer prevention. Trends Mol Med 2004, 10(7), 324-330.
22. Ridnour LA, Thomas DD, Mancardi D, et al. The chemistry of nitrosative stress induced by nitric oxide and reactive nitrogen oxide species. Putting perspective on stressful biological situations. Biol Chem 2004, 385(1), 1-10.
23. Crowell JA, Steele VE, Sigman CC, et al. Is inducible nitric oxide synthase a target for chemoprevention? Mol Cancer Ther 2003,2(8), 815-823.
24. Bak AW, McKnight W, Li P, et al. Cyclooxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma. Life Sci 1998, 62(23), PL367-PL373.
25. Kashfi K, Ryan Y, Qiao LL, et al. Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells, evidence of a tissue type-independent effect. J Pharmacol Exp Ther 2002, 303(3), 1273-1282.
26. Kaza CS, Kashfi K, Rigas B. Colon cancer prevention with NO-releasing NSAIDs. Prostaglandins Other Lipid Mediat 2002, 67(2), 107-120.
27. Moskowitz DW, Johnson FE. The central role of angiotensin I-converting enzyme in vertebrate pathophysiology. Curr Top Med Chem 2004, 4(13), 1433-1454.
28. Berry C, Touyz R, Dominiczak AF, et al. Angiotensin receptors, signaling, vascular pathophysiology, and interactions with ceramide. Am J Physiol Heart Circ Physiol 2001, 281(6), H2337-H2365.
29. Lever AF, Hole DJ, Gillis CR, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998, 352(9123), 179-184.
30. Plummer SM, Holloway KA, Manson MM, et al. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene 1999, 18(44), 6013-6020.
31. St-Germain ME, Gagnon V, Parent S, et al. Regulation of COX-2 protein expression by Akt in endometrial cancer cells is mediated through NF-kappaB/IkappaB pathway. Mol Cancer 2004, 3(1), 7.
32. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2(7), 489-501.
33. Bellacosa A, Testa JR, Moore R, et al. A portrait of AKT kinases, human cancer and animal models depict a family with strong individualities. Cancer Biol Ther 2004, 3(3), 268-275.
34. Mitsiades CS, Mitsiades N, Koutsilieris M. The Akt pathway, molecular targets for anti-cancer drug development. Curr Cancer Drug Targets 2004, 4(3), 235-256.
35. Lu Y, Wang H, Mills GB. Targeting PI3K-AKT pathway for cancer therapy. Rev Clin Exp Hematol 2003, 7(2), 205-228.
36. Paez J, Sellers WR. PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling. Cancer Treat Res 2003, 115, 145-167.
37. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304(5670), 554.
38. West KA, Brognard J, Clark AS, et al. Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest 2003, 111(1), 81-90.
39. West KA, Linnoila IR, Belinsky SA, et al. Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3′-kinase/Akt pathway in vitro and in vivo. Cancer Res 2004, 64(2), 446-451.
40. Castillo SS, Brognard J, Petukhov PA, et al. Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues. Cancer Res 2004, 64(8), 2782-2792.
41. Chainani-Wu N. Safety and anti-inflammatory activity of curcumin, a component of tumeric (Curcuma longa). J Altern Complement Med 2003, 9(1), 161-168.
42. Chauhan DP. Chemotherapeutic potential of curcumin for colorectal cancer. Curr Pharm Des 2002, 8(19), 1695-1706.
43. Leu TH, Maa MC. The molecular mechanisms for the anti-tumourigenic effect of curcumin. Curr Med Chem Anti-Canc Agents 2002, 2(3), 357-370.
44. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin, preclinical and clinical studies. Anticancer Res 2003, 23(1A), 363-398.
45. Sharma RA, McLelland HR, Hill KA, et al. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 2001, 7(7), 1894-1900.
46. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001, 21(4B), 2895-2900.
47. Garcea G, Berry DP, Jones DJ, et al. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 2005, 14(1), 120-125.
48. Jong L, Chao WR, Amin K, et al. SR13668, a novel indole derived inhibitor of phospho-Akt potently suppresses tumour growth in various murine xenograft models. Proc Am Assoc Cancer Res 2004, 45., abst. no. 3684.
49. Udeani GO, Zhao GM, Shin YG, et al. Pharmacokinetics of deguelin, a cancer chemopreventive agent in rats. Cancer Chemother Pharmacol 2001, 47(3), 263-268.
50. Chun KH, Kosmeder 2nd JW, Sun S, et al. Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J Natl Cancer Inst 2003, 95(4), 291-302.
51. Lee HY, Suh YA, Kosmeder JW, et al. Deguelin-induced inhibition of cyclooxygenase-2 expression in human bronchial epithelial cells. Clin Cancer Res 2004, 10(3), 1074-1079.
52. Murillo G, Kosmeder 2nd JW, Pezzuto JM, et al. Deguelin suppresses the formation of carcinogen-induced aberrant crypt foci in the colon of CF-1 mice. Int J Cancer 2003, 104(1), 7-11.
53. Udeani GO, Gerhauser C, Thomas CF, et al. Cancer chemopreventive activity mediated by deguelin, a naturally occurring rotenoid. Cancer Res 1997, 57(16), 3424-3428.
54. Ito C, Itoigawa M, Kojima N, et al. Cancer chemopreventive activity of rotenoids from Derris trifoliata. Planta Med 2004, 70(1), 8-11.
55. Fang N, Casida JE. Anticancer action of cube insecticide, correlation for rotenoid constituents between inhibition of NADH,ubiquinone oxidoreductase and induced ornithine decarboxylase activities. Proc Natl Acad Sci USA 1998, 95(7), 3380-3384.
56. Lorberg A, Hall MN. TOR, the first 10 years. Curr Top Microbiol Immunol 2004, 279, 1-18.
57. Shamji AF, Nghiem P, Schreiber SL. Integration of growth factor and nutrient signaling, implications for cancer biology. Mol Cell 2003, 12(2), 271-280.
58. Martin KA, Blenis J. Coordinate regulation of translation by the PI 3-kinase and mTOR pathways. Adv Cancer Res 2002, 86, 1-39.
59. Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 2000, 19(56), 6680-6686.
60. Fingar DC, Richardson CJ, Tee AR, et al. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 2004, 24(1), 200-216.
61. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001, 15(7), 807-826.
62. Gingras AC, Raught B, Sonenberg N. mTOR signaling to translation. Curr Top Microbiol Immunol 2004, 279, 169-197.
63. Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 2003, 3(4), 371-377.
64. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003, 349(4), 366-381.
65. Shayesteh L, Lu Y, Kuo WL, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999, 21(1), 99-102.
66. Tee AR, Fingar DC, Manning BD, et al. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci USA 2002, 99(21), 13571-13576.
67. Inoki K, Li Y, Zhu T, et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002, 4(9), 648-657.
68. Manning BD, Tee AR, Logsdon MN, et al. Identification of the tuberous sclerosis complex-2 tumour suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/Akt pathway. Mol Cell 2002, 10(1), 151-162.
69. Louro ID, McKie-Bell P, Gosnell H, et al. The zinc finger protein GLI induces cellular sensitivity to the mTOR inhibitor rapamycin. Cell Growth Differ 1999, 10(7), 503-516.
70. Bushman JL. Green tea and cancer in humans, a review of the literature. Nutr Cancer 1998, 31(3), 151-159.
71. Higdon JV, Frei B. Tea catechins and polyphenols, health effects, metabolism, and antioxidant functions. Crit Rev Food Sci Nutr 2003, 43(1), 89-143.
72. Yang CS, Yang GY, Chung JY, et al. Tea and tea polyphenols in cancer prevention. Adv Exp Med Biol 2001, 492, 39-53.
73. Yang CS, Maliakal P, Meng X. Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol 2002, 42, 25-54.
74. Shimizu M, Deguchi I, Lim JT, et al. (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. Clin Cancer Res 2005, 11(7), 2735-2746.
75. Chow HH, Cai Y, Hakim IA, et al. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res 2003, 9(9), 3312-3319.
76. Chow HH-S, Hakim IA, Vining DR, et al. Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals. Cancer Epidemiol Biomarkers Prev 2005, 11(12), 4627-4633.
77. Masuda M, Suzui M, Lim JT, et al. Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells. Clin Cancer Res 2003, 9(9), 3486-3491.
78. Cook LS, Goldoft M, Schwartz SM, et al. Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. J Urol 1999, 161(1), 152-155.
79. Dai Q, Franke AA, Jin F, et al. Urinary excretion of phytoestrogens and risk of breast cancer among Chinese women in Shanghai. Cancer Epidemiol Biomarkers Prev 2002, 11(9), 815-821.
80. Wu AH, Wan P, Hankin J, et al. Adolescent and adult soy intake and risk of breast cancer in Asian-Americans. Carcinogenesis 2002, 23(9), 1491-1496.
81. Adlercreutz H, Honjo H, Higashi A, et al. Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet. Am J Clin Nutr 1991, 54(6), 1093-1100.
82. Adlercreutz H, Markkanen H, Watanabe S. Plasma concentrations of phyto-oestrogens in Japanese men. Lancet 1993, 342(8881), 1209-1210.
83. Casanova M, You L, Gaido KW, et al. Developmental effects of dietary phytoestrogens in Sprague-Dawley rats and interactions of genistein and daidzein with rat estrogen receptors alpha and beta in vitro. Toxicol Sci 1999, 51(2), 236-244.
84. Gescher A, Pastorino U, Plummer SM, et al. Suppression of tumour development by substances derived from the diet-mechanisms and clinical implications. Br J Clin Pharmacol 1998, 45(1), 1-12.
85. Nevala R, Lassila M, Finckenberg P, et al. Genistein treatment reduces arterial contractions by inhibiting tyrosine kinases in ovariectomized hypertensive rats. Eur J Pharmacol 2002, 452(1), 87-96.
86. Fotsis T, Pepper M, Adlercreutz H, et al. Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci USA 1993, 90(7), 2690-2694.
87. Shao ZM, Alpaugh ML, Fontana JA, et al. Genistein inhibits proliferation similarly in estrogen receptor-positive and negative human breast carcinoma cell lines characterized by P21WAF1/CIP1 induction, G2/M arrest, and apoptosis. J Cell Biochem 1998, 69(1), 44-54.
88. Yoon HS, Moon SC, Kim ND, et al. Genistein induces apoptosis of RPE-J cells by opening mitochondrial PTP. Biochem Biophys Res Commun 2000, 276(1), 151-156.
89. Constantinou AI, Krygier AE, Mehta RR. Genistein induces maturation of cultured human breast cancer cells and prevents tumour growth in nude mice. Am J Clin Nutr 1998, 68(6 Suppl.), 1426S-1430S.
90. Pollard M, Luckert PH. Influence of isoflavones in soy protein isolates on development of induced prostate-related cancers in L-W rats. Nutr Cancer 1997, 28(1), 41-45.
91. Kato K, Takahashi S, Cui L, et al. Suppressive effects of dietary genistin and daidzin on rat prostate carcinogenesis. Jpn J Cancer Res 2000, 91(8), 786-791.
92. Lamartiniere CA, Moore JB, Brown NM, et al. Genistein suppresses mammary cancer in rats. Carcinogenesis 1995, 16(11), 2833-2840.
93. Jin Z, MacDonald RS. Soy isoflavones increase latency of spontaneous mammary tumours in mice. J Nutr 2002, 132(10), 3186-3190.
94. Fischer L, Mahoney C, Jeffcoat AR, et al. Clinical characteristics and pharmacokinetics of purified soy isoflavones, multiple-dose administration to men with prostate neoplasia. Nutr Cancer 2004, 48(2), 160-170.
95. Takimoto CH, Glover K, Huang X, et al. Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancer. Cancer Epidemiol Biomarkers Prev 2003, 12(11 Pt 1), 1213-1221.
96. Miltyk W, Craciunescu CN, Fischer L, et al. Lack of significant genotoxicity of purified soy isoflavones (genistein, daidzein, and glycitein) in 20 patients with prostate cancer. Am J Clin Nutr 2003, 77(4), 875-882.
97. Busby MG, Jeffcoat AR, Bloedon LT, et al. Clinical characteristics and pharmacokinetics of purified soy isoflavones, single-dose administration to healthy men. Am J Clin Nutr 2002, 75(1), 126-136.
98. Bloedon LT, Jeffcoat AR, Lopaczynski W, et al. Safety and pharmacokinetics of purified soy isoflavones, single-dose administration to postmenopausal women. Am J Clin Nutr 2002, 76(5), 1126-1137.
99. Giovannucci E. A review of epidemiologic studies of tomatoes, lycopene, and prostate cancer. Exp Biol Med (Maywood) 2002, 227(10), 852-859.
100. Giovannucci E, Rimm EB, Liu Y, et al. A prospective study of tomato products, lycopene, and prostate cancer risk. J Natl Cancer Inst 2002, 94(5), 391-398.
101. Chen L, Stacewicz-Sapuntzakis M, Duncan C, et al. Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. J Natl Cancer Inst 2001, 93(24), 1872-1879.
102. Herzog A, Siler U, Spitzer V, et al. Lycopene reduced gene expression of steroid targets and inflammatory markers in normal rat prostate. FASEB J 2005, 19(2), 272-274.
103. Siler U, Barella L, Spitzer V, et al. Lycopene and vitamin E interfere with autocrine/paracrine loops in the Dunning prostate cancer model. FASEB J 2004, 18(9), 1019-1021.
104. Kucuk O, Sarkar FH, Djuric Z, et al. Effects of lycopene supplementation in patients with localized prostate cancer. Exp Biol Med (Maywood) 2002, 227(10), 881-885.
105. Michnovicz JJ, Bradlow HL. Induction of estradiol metabolism by dietary indole-3-carbinol in humans. J Natl Cancer Inst 1990, 82(11), 947-949.
106. Newfield L, Goldsmith A, Bradlow HL, et al. Estrogen metabolism and human papillomavirus-induced tumours of the larynx, chemo-prophylaxis with indole-3-carbinol. Anticancer Res 1993, 13(2), 337-341.
107. Coll DA, Rosen CA, Auborn K, et al. Treatment of recurrent respiratory papillomatosis with indole-3-carbinol. Am J Otolaryngol 1997, 18(4), 283-285.
108. Rosen CA, Bryson PC. Indole-3-carbinol for recurrent respiratory papillomatosis, long-term results. J Voice 2004, 18(2), 248-253.
109. Bell MC, Crowley-Nowick P, Bradlow HL, et al. Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. Gynecol Oncol 2000, 78(2), 123-129.
110. Grubbs CJ, Steele VE, Casebolt T, et al. Chemoprevention of chemically-induced mammary carcinogenesis by indole-3-carbinol. Anticancer Res 1995, 15(3), 709-716.
111. Kojima T, Tanaka T, Mori H. Chemoprevention of spontaneous endometrial cancer in female Donryu rats by dietary indole-3-carbinol. Cancer Res 1994, 54(6), 1446-1449.
112. Jin L, Qi M, Chen DZ, et al. Indole-3-carbinol prevents cervical cancer in human papilloma virus type 16 (HPV 16) transgenic mice. Cancer Res 1999, 59(16), 3991-3997.
113. El-Bayoumy K, Upadhyaya P, Desai DH, et al. Effects of 1;4-phenylenebis(methylene)selenocyanate, phenethyl isothiocyanate, indole-3-carbinol, and d-limonene individually and in combination on the tumourigenicity of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanone in A/J mouse lung. Anticancer Res 1996, 16(5A), 2709-2712.
114. Stoner G, Casto B, Ralston S, et al. Development of a multi-organ rat model for evaluating chemopreventive agents, efficacy of indole-3-carbinol. Carcinogenesis 2002, 23(2), 265-272.
115. Grose KR, Bjeldanes LF. Oligomerization of indole-3-carbinol in aqueous acid. Chem Res Toxicol 1992, 5(2), 188-193.
116. Arneson DWHA, McMahon LM, Robaugh D. Presence of 3,3′- diindolylmethane in human plasma after oral administration of indole-3-carbinol. Proc Am Assoc Cancer Res 1999, 40.
117. McDougal A, Sethi Gupta M, Ramamoorthy K, et al. Inhibition of carcinogen-induced rat mammary tumour growth and other estrogen-dependent responses by symmetrical dihalo-substituted analogs of diindolylmethane. Cancer Lett 2000, 151(2), 169-179.
118. Le HT, Schaldach CM, Firestone GL, et al. Plant-derived 3,3′-diindolylmethane is a strong androgen antagonist in human prostate cancer cells. J Biol Chem 2003, 278(23), 21136-21145.
119. Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997, 275(5297), 218-220.
120. Banerjee S, Bueso-Ramos C, Aggarwal BB. Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol, role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res 2002, 62(17), 4945-4954.
121. Bhat KP, Lantvit D, Christov K, et al. Estrogenic and antiestrogenic properties of resveratrol in mammary tumour models. Cancer Res 2001, 61(20), 7456-7463.
122. Bhat KPL, Kosmeder 2nd JW, Pezzuto JM. Biological effects of resveratrol. Antioxid Redox Signal 2001, 3(6), 1041-1064.
123. Gusman J, Malonne H, Atassi G. A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis 2001, 22(8), 1111-1117.
124. Joe AK, Liu H, Suzui M, et al. Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin Cancer Res 2002, 8(3), 893-903.
125. Schneider Y, Duranton B, Gosse F, et al. Resveratrol inhibits intestinal tumourigenesis and modulates host-defense-related gene expression in an animal model of human familial adenomatous polyposis. Nutr Cancer 2001, 39(1), 102-107.
126. Manna SK, Mukhopadhyay A, Aggarwal BB. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappaB, activator protein-1, and apoptosis, potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol 2000, 164(12), 6509-6519.
127. She QB, Huang C, Zhang Y, et al. Involvement of c-jun NH(2)-terminal kinases in resveratrol-induced activation of p53 and apoptosis. Mol Carcinog 2002, 33(4), 244-250.
128. Adhami VM, Afaq F, Ahmad N. Involvement of the retinoblastoma (pRb)-E2F/DP pathway during antiproliferative effects of resveratrol in human epidermoid carcinoma (A431) cells. Biochem Biophys Res Commun 2001, 288(3), 579-585.
129. Martinez J, Moreno JJ. Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. Biochem Pharmacol 2000, 59(7), 865-870.
130. Surh YJ, Chun KS, Cha HH, et al. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals, down-regulation of COX-2 and iNOS through suppression of NF-kappaB activation. Mutat Res 2001, 480-481, 243-268.
131. Fremont L. Biological effects of resveratrol. Life Sci 2000, 66(8), 663-673.
132. Docherty JJ, Smith JS, Fu MM, et al. Effect of topically applied resveratrol on cutaneous herpes simplex virus infections in hairless mice. Antiviral Res 2004, 61(1), 19-26.
133. Gehm BD, McAndrews JM, Chien PY, et al. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci USA 1997, 94(25), 14138-14143.
134. Ramsey TL, Risinger KE, Jernigan SC, et al. Estrogen receptor beta isoforms exhibit differences in ligand-activated transcriptional activity in an estrogen response element sequence-dependent manner. Endocrinology 2004, 145(1), 149-160.
135. Harris HA, Albert LM, Leathurby Y, et al. Evaluation of an estrogen receptor-beta agonist in animal models of human disease. Endocrinology 2003, 144(10), 4241-4249.
136. Gustafsson JA. What pharmacologists can learn from recent advances in estrogen signalling. Trends Pharmacol Sci 2003, 24(9), 479-485.
137. Paruthiyil S, Parmar H, Kerekatte V, et al. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumour formation by causing a G2 cell cycle arrest. Cancer Res 2004, 64(1), 423-428.
138. Weihua Z, Andersson S, Cheng G, et al. Update on estrogen signaling. FEBS Lett 2003, 546(1), 17-24.
139. Dotzlaw H, Leygue E, Watson PH, et al. Expression of estrogen receptor-beta in human breast tumours. J Clin Endocrinol Metab 1997, 82(7), 2371-2374.
140. Latil A, Bieche I, Vidaud D, et al. Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res 2001, 61(5), 1919-1926.
141. Foley EF, Jazaeri AA, Shupnik MA, et al. Selective loss of estrogen receptor beta in malignant human colon. Cancer Res 2000, 60(2), 245-248.
142. Brandenberger AW, Tee MK, Jaffe RB. Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines, down-regulation of ER-beta in neoplastic tissues. J Clin Endocrinol Metab 1998, 83(3), 1025-1028.
143. Akgun H, Lechago J, Younes M. Estrogen receptor-beta is expressed in Barrett's metaplasia and associated adenocarcinoma of the esophagus. Anticancer Res 2002, 22(3), 1459-1461.
144. Horvath LG, Henshall SM, Lee CS, et al. Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Res 2001, 61(14), 5331-5335.
145. Pasquali D, Rossi V, Esposito D, et al. Loss of estrogen receptor beta expression in malignant human prostate cells in primary cultures and in prostate cancer tissues. J Clin Endocrinol Metab 2001, 86(5), 2051-2055.
146. Fixemer T, Remberger K, Bonkhoff H. Differential expression of the estrogen receptor beta (ERbeta) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma. Prostate 2003, 54(2), 79-87.
147. Tsurusaki T, Aoki D, Kanetake H, et al. Zone-dependent expression of estrogen receptors alpha and beta in human benign prostatic hyperplasia. J Clin Endocrinol Metab 2003, 88(3), 1333-1340.
148. Nojima D, Li LC, Dharia A, et al. CpG hypermethylation of the promoter region inactivates the estrogen receptor-beta gene in patients with prostate carcinoma. Cancer 2001, 92(8), 2076-2083.
149. Sasaki M, Tanaka Y, Perinchery G, et al. Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer. J Natl Cancer Inst 2002, 94(5), 384-390.
150. Zhu X, Leav I, Leung YK, et al. Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. Am J Pathol 2004, 164(6), 2003-2012.
151. Linja MJ, Savinainen KJ, Tammela TL, et al. Expression of ERalpha and ERbeta in prostate cancer. Prostate 2003, 55(3), 180-186.
152. Leav I, Lau KM, Adams JY, et al. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol 2001, 159(1), 79-92.
153. Fujimura T, Takahashi S, Urano T, et al. Differential expression of estrogen receptor beta (ERbeta) and its C-terminal truncated splice variant ERbetacx as prognostic predictors in human prostatic cancer. Biochem Biophys Res Commun 2001, 289(3), 692-699.
154. Kensler TW, Egner PA, Wang JB, et al. Strategies for chemoprevention of liver cancer. Eur J Cancer Prev 2002, 11(Suppl. 2), S58-S64.
155. Nelson WG, De Marzo AM, DeWeese TL. The molecular pathogenesis of prostate cancer. Implications for prostate cancer prevention. Urology 2001, 57(4 Suppl. 1), 39-45.
156. Cai H, Hudson EA, Mann P, et al. Growth-inhibitory and cell cycle-arresting properties of the rice bran constituent tricin in human-derived breast cancer cells in vitro and in nude mice in vivo. Br J Cancer 2004, 91(7), 1364-1371.
157. Ip C, Dong Y, Ganther HE. New concepts in selenium chemoprevention. Cancer Metastasis Rev 2002, 21(3-4), 281-289.
158. Posner GH, Woodard BT, Crawford KR, et al. 2,2-Disubstituted analogues of the natural hormone 1 alpha,25-dihydroxyvitamin D(3), chemistry and biology. Bioorg Med Chem 2002, 10(7), 2353-2365.
159. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000, 44(1), 235-249.
160. Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001, 46(1-3), 3-26.
161. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100(1), 57-70.
162. Cheng J, Imanishi H, Liu W, et al. Involvement of cell cycle regulatory proteins and MAP kinase signaling pathway in growth inhibition and cell cycle arrest by a selective cyclooxygenase 2 inhibitor, etodolac, in human hepatocellular carcinoma cell lines. Cancer Sci 2004, 95(8), 666-673.
163. Wu T, Leng J, Han C, et al. The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells. Mol Cancer Ther 2004, 3(3), 299-307.
164. Dannenberg AJ, Lippman SM, Mann JR, et al. Cyclooxygenase-2 and epidermal growth factor receptor, pharmacologic targets for chemoprevention. J Clin Oncol 2005, 23(2), 254-266.
165. Kyle E, Neckers L, Takimoto C, et al. Genistein-induced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity. Mol Pharmacol 1997, 51(2), 193-200.
166. Henderson BE, Ross RK, Shibata A, et al. Environmental carcinogens and anticarcinogens. In Wattenberg L, Lipkin M, Boone CW, et al., eds. Cancer chemoprevention. Boca Raton (FL), CRC Press, 1992. pp. 3-17.
167. Sharma S, Stutzman JD, Kelloff GJ, et al. Screening of potential chemopreventive agents using biochemical markers of carcinogenesis. Cancer Res 1994, 54(22), 5848-5855.
168. Prochaska HJ, Santamaria AB. Direct measurement of NAD (P)H,quinone reductase from cells cultured in microtiter wells, a screening assay for anticarcinogenic enzyme inducers. Anal Biochem 1988, 169(2), 328-336.
169. Wattenberg LW. Inhibitors of chemical carcinogenesis. Adv Cancer Res 1978, 26, 197-226.
170. Bertram B, Frei E, Wiessler M. Influence of disulfiram on glutathione, glutathione-S-transferase, and on nitrosaminedealkylases of liver, kidney and esophagus. Biochem Pharmacol 1985, 34, 387-388.
171. Kelloff GJ, Fay JR, Steele VE, et al. Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 1996, 5(8), 657-666.
172. Fry DW, Kraker AJ, McMichael A, et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994, 265(5175), 1093-1095.
173. Weinstein IB, Arcoleo J, Backer J, et al. Molecular mechanisms of tumour promotion and multistage carcinogenesis. Princess Takamatsu Symp 1983, 14, 59-74.
174. Kim TE, Murren JR. Lapatinib ditosylate GlaxoSmithKline. IDrugs 2003, 6(9), 886-893.
175. Perchellet JP, Owen MD, Posey TD, et al. Inhibitory effects of glutathione level-raising agents and D-alpha-tocopherol on ornithine decarboxylase induction and mouse skin tumour promotion by 12-O- tetradecanoylphorbol-13-acetate. Carcinogenesis 1985, 6(4), 567-573.
176. Lichti U, Patterson E, Hennings H, et al. Differential retinoic acid inhibition of ornithine decarboxylase induction by 12-O-tetradecanoylphorbol-13- acetate and by germicidal ultraviolet light. Cancer Res 1981, 41(1), 49-54.
177. Pegg AE, Shantz LM, Coleman CS. Ornithine decarboxylase as a target for chemoprevention. J Cell Biochem Suppl 1995, 22, 132-138.
178. Sharma S, Ghoddoussi M, Gao P, et al. A quantitative angiogenesis model for efficacy testing of chemopreventive agents. Anticancer Res 2001, 21(6A), 3829-3837.
179. Compton MM. A biochemical hallmark of apoptosis, internucleosomal degradation of the genome. Cancer Metastasis Rev 1992, 11(2), 105-119.
180. Schmid I, Uittenbogaart CH, Keld B, et al. A rapid method for measuring apoptosis and dual-color immunofluorescence by single laser flow cytometry. J Immunol Methods 1994, 170(2), 145-157.
181. Lotan R. Roles of retinoids and their nuclear receptors in the
182. Muccio DD, Brouillette WJ, Alam M, et al. Conformationally defined 6-s-trans-retinoic acid analogs. 3. Structure-activity relationships for nuclear receptor binding, transcriptional activity, and cancer chemopreventive activity. J Med Chem 1996, 39(19), 3625-3635.
183. Steele VE, Boone CW, Lubet RA, et al. Preclinical drug development paradigms for chemopreventives. Hematol Oncol Clin North Am 1998, 12(5), 943-961., v-vi.
184. Shay JW, Werbin H, Wright WE. Telomerase assays in the diagnosis and prognosis of cancer. Ciba Found Symp 1997, 211, 148-155., discussion 155-159.
185. Boone CW, Lieberman R, Mairinger T, et al. Computer-assisted image analysis-derived intermediate endpoints. Urology 2001, 57(4Suppl. 1), 1129-1131.
186. Bogdanov Jr AA, Lin CP, Simonova M, et al. Cellular activation of the self-quenched fluorescent reporter probe in tumour microenvironment. Neoplasia 2002, 4(3), 228-236.
187. Rafferty TS, Green MH, Lowe JE, et al. Effects of selenium compounds on induction of DNA damage by broadband ultraviolet radiation in human keratinocytes. Br J Dermatol 2003, 148(5), 1001-1009.
188. Stoyanova R, Clapper ML, Bellacosa A, et al. Altered gene expression in phenotypically normal renal cells from carriers of tumour suppressor gene mutations. Cancer Biol Ther 2004, 3(12), 1313-1321.
189. Arnold JT, Wilkinson BP, Sharma S, et al. Evaluation of chemopreventive agents in different mechanistic classes using a rat tracheal epithelial cell culture transformation assay. Cancer Res 1995, 55(3), 537-543.
190. Korytynski EA, Kelloff GJ, Suk WA, et al. The development of an anchorage-independence assay using human lung tumour cells to screen potential chemopreventive agents. Anticancer Res 1996, 16(3A), 1091-1094.
191. Mehta RG, Steele V, Kelloff GJ, et al. Influence of thiols and inhibitors of prostaglandin biosynthesis on the carcinogen-induced development of mammary lesions in vitro. Anticancer Res 1991, 11(2), 587-591.
192. Steele VE, Sharma S, Mehta R, et al. Use of in vitro assays to predict the efficacy of chemopreventive agents in whole animals. J Cell Biochem Suppl 1996, 26, 29-53.
193. Bern HA, Nandi S. Recent studies of the hormonal influence in mouse mammary tumourigenesis. Prog Exp Tumour Res 1961, 2, 90-144.
194. Normann TC. Neurosecretion by exocytosis. Int Rev Cytol 1976, 46, 1-77.
195. Wood BG, Washburn LL, Mukherjee AS, et al. Hormonal regulation of lobulo-alveolar growth, functional differentiation and regression of whole mouse mammary gland in organ culture. J Endocrinol 1975, 65(1), 1-6.
196. Thompson HJ, McGinley JN, Rothhammer K, et al. Rapid induction of mammary intraductal proliferations, ductal carcinoma in situ and carcinomas by the injection of sexually immature female rats with 1-methyl-1-nitrosourea. Carcinogenesis 1995, 16(10), 2407-2411.
197. Bird RP. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen, preliminary findings. Cancer Lett 1987, 37(2), 147-151.
198. Pereira MA, Barnes LH, Rassman VL, et al. Use of azoxymethane-induced foci of aberrant crypts in rat colon to identify potential cancer chemopreventive agents. Carcinogenesis 1994, 15(5), 1049-1054.
199. Steele VE, Moon RC, Lubet RA, et al. Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models, methods and results from the NCI Chemoprevention Drug Development Program. J Cell Biochem Suppl 1994, 20, 32-54.
200. Stoner GD. Lung tumours in strain A mice as a bioassay for carcinogenicity of environmental chemicals. Exp Lung Res 1991, 17(2), 405-423.
201. Lubet R, Wang Y, Zhang Z, et al. Mouse models incorporating alterations in the major tumour suppressor genes P53 and P16, their use in screening for potential carcinogens, developing further relevant mouse models, and screening for potential chemopreventive and chemotherapetutic agents. Exp Lung Res 2005, 31(1), 117-133.
202. Estensen RD, Jordan MM, Wiedmann TS, et al. Effect of chemopreventive agents on separate stages of progression of benzo[a]pyrene induced lung tumours in A/J mice. Carcinogenesis 2004, 25(2), 197-201.
203. Moon RC, Rao KV, Detrisac CJ, et al. Hamster lung cancer model of carcinogenesis and chemoprevention. Adv Exp Med Biol 1992, 320, 55-61.
204. Solt DB, Chang K, Helenowski I, et al. Phenethyl isothiocyanate inhibits nitrosamine carcinogenesis in a model for study of oral cancer chemoprevention. Cancer Lett 2003, 202(2), 147-152.
205. Gerson SJ. Oral cancer. Crit Rev Oral Biol Med 1990, 1(3), 153-166.
206. Tanaka T, Makita H, Ohnishi M, et al. Chemoprevention of 4-nitroquinoline 1-oxide-induced oral carcinogenesis by dietary curcumin and hesperidin, comparison with the protective effect of beta-carotene. Cancer Res 1994, 54(17), 4653-4659.
207. Boone CW, Kelloff GJ, Malone WE. Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials, a review. Cancer Res 1990, 50(1), 2-9.
208. Su LK, Kinzler KW, Vogelstein B, et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 1992, 256(5057), 668-670.
209. Edelmann W, Yang K, Kuraguchi M, et al. Tumourigenesis in Mlh1 and Mlh1/Apc1638N mutant mice. Cancer Res 1999, 59(6), 1301-1307.
210. Cooper HS, Everley L, Chang WC, et al. The role of mutant Apc in the development of dysplasia and cancer in the mouse model of dextran sulfate sodium-induced colitis. Gastroenterology 2001, 121(6), 1407-1416.
211. Cooper HS, Murthy S, Kido K, et al. Dysplasia and cancer in the dextran sulfate sodium mouse colitis model. Relevance to colitis-associated neoplasia in the human, a study of histopathology, B-catenin and p53 expression and the role of inflammation. Carcinogenesis 2000, 21(4), 757-768.
212. Goldstein SR, Yang GY, Curtis SK, et al. Development of esophageal metaplasia and adenocarcinoma in a rat surgical model without the use of a carcinogen. Carcinogenesis 1997, 18(11), 2265-2270.
213. Clark GW, Smyrk TC, Mirvish SS, et al. Effect of gastroduodenal juice and dietary fat on the development of Barrett's esophagus and esophageal neoplasia, an experimental rat model. Ann Surg Oncol 1994, 1(3), 252-261.
214. Moon RC, Mehta RG. Chemoprevention of experimental carcinogenesis in animals. Prev Med 1989, 18(5), 576-591.
215. McCormick DL, Adamowski CB, Fiks A, et al. Lifetime dose-response relationships for mammary tumour induction by a single administration of N-methyl-N-nitrosourea. Cancer Res 1981, 41(5), 1690-1694.
216. Moon RC, Kelloff GJ, Detrisac CJ, et al. Chemoprevention of MNU-induced mammary tumours in the mature rat by 4-HPR and tamoxifen. Anticancer Res 1992, 12(4), 1147-1153.
217. Maroulakou IG, Anver M, Garrett L, et al. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumour antigen fusion gene. Proc Natl Acad Sci USA 1994, 91(23), 11236-11240.
218. Gould MN. The introduction of activated oncogenes to mammary cells in vivo using retroviral vectors, a new model for the chemoprevention of premalignant and malignant lesions of the breast. J Cell Biochem Suppl 1993, 17G, 66-72.
219. Bosland MC. Use of animal models in defining efficacy of chemoprevention agents against prostate cancer. Eur Urol 1999, 35(5-6), 459-463.
220. Greenberg NM, DeMayo F, Finegold MJ, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995, 92(8), 3439-3443.
221. Becci PJ, Thompson HJ, Strum JM, et al. N-butyl-N-(4-hydroxybutyl) nitrosamine-induced urinary bladder cancer in C57BL/6 X DBA/2 F1 mice as a useful model for study of chemoprevention of cancer with retinoids. Cancer Res 1981, 41(3), 927-932.
222. McCormick DL, Moon RC. Antipromotional activity of dietary N-(4-hydroxyphenyl)retinamide in two-stage skin tumourigenesis in CD-1 and SENCAR mice. Cancer Lett 1986, 31(2), 133-138.
223. Warren BS, Slaga TJ. Mechanisms of inhibition of tumour progression. Basic Life Sci 1993, 61, 279-289.
224. DiGiovanni J. Multistage carcinogenesis in mouse skin. Pharmacol Ther 1992, 54(1), 63-128.
225. Forbes PD, Beer JZ, Black HS, et al. Standardized protocols for photocarcinogenesis safety testing. Front Biosci 2003, 8, d848-d854.
226. Arbeit JM. Mouse models of cervical cancer. Comp Med 2003, 53(3), 256-258.
227. Nishida T, Sugiyama T, Kataoka A, et al. Histologic characterization of rat ovarian carcinoma induced by intraovarian insertion of a 7,12-dimethylbenz[a]anthracene-coated suture, common epithelial tumours of the ovary in rats. Cancer 1998, 83(5), 965-970.
228. Fredrickson TN. Ovarian tumours of the hen. Environ Health Perspect 1987, 73, 35-51.
229. Sivaraman L, Gay J, Hilsenbeck SG, et al. Effect of selective ablation of proliferating mammary epithelial cells on MNU induced rat mammary tumourigenesis. Breast Cancer Res Treat 2002, 73(1), 75-83.
230. Li Y, Welm B, Podsypanina K, et al. Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc Natl Acad Sci USA 2003, 100(26), 15853-15858.
231. Smalley M, Ashworth A. Stem cells and breast cancer, a field in transit. Nat Rev Cancer 2003, 3(11), 832-844.
232. Dick JE. Breast cancer stem cells revealed. Proc Natl Acad Sci USA 2003, 100(7), 3547-3549.
233. Welm BE, Tepera SB, Venezia T, et al. Sca-1 (pos) cells in the mouse mammary gland represent an enriched progenitor cell population. Dev Biol 2002, 245(1), 42-56.
234. Wax A, Yang C, Muller MG, et al. In situ detection of neoplastic transformation and chemopreventive effects in rat esophagus epithelium using angle-resolved low-coherence interferometry. Cancer Res 2003, 63(13), 3556-3559.
235. Kelloff GJ, Johnson JR, Crowell JA, et al. Approaches to the development and marketing approval of drugs that prevent cancer. Cancer Epidemiol Biomarkers Prev 1995, 4(1), 1-10.
236. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumours. N Engl J Med 1989, 320(8), 479-484.
237. Fisher B, Powles TJ, Pritchard KJ. Tamoxifen for the prevention of breast cancer. Eur J Cancer 2000, 36(2), 142-150.
238. Drazen JM. COX-2 inhibitors - a lesson in unexpected problems. N Engl J Med 2005, 352(11), 1131-1132.
239. Psaty BM, Furberg CD. COX-2 inhibitors - lessons in drug safety. N Engl J Med 2005, 352(11), 1133-1135.